An immunogenic cell death-related lncRNA signature correlates with prognosis and tumor immune microenvironment in bladder cancer

Author:

Luo Jinhong,Luo Feiye,Li Qin,Liu Qinghong,Wang Jinshan

Abstract

AbstractImmunogenic cell death (ICD) is a newly discovered form of cellular demise that triggers adaptive immune responses mediated by T cells. However, the immunogenic cell death-related lncRNAs (ICDRLs) involved in bladder cancer (BC) development and progression remain to be further elucidated. Molecular profiling data and clinicopathological information for BC patients were obtained from TCGA, and the ICDRGs list was obtained from published literature. For the identification of ICDRLs, Pearson co-expression analysis was performed, and a prognostic signature based on 13 ICDRLs was constructed by univariate assays and LASSO assays. Herein, an ICDRLSig consisting of 13 ICDRLs was constructed. KM curves and ROC curves demonstrated that the constructed signature in the TCGA training, testing, entire and external sets have good predictive performance. Multivariate assays illuminated that the signature is an independent predictor for BC patients’ OS, exhibiting greater predictive power for the survival than traditional clinicopathological features. Additionally, patients in the high-ICDRLSig risk subgroup had more abundant immune infiltration, higher immune checkpoint gene expression, lower TMB and poorer response to immunotherapy. We have developed a novel ICDRLSig that can be exploited for survival prediction and provide a reference for further individualized treatment.

Funder

Science and Technology Plan of Jiangxi Health Commission

Publisher

Springer Science and Business Media LLC

Reference39 articles.

1. DeGeorge, K. C., Holt, H. R. & Hodges, S. C. Bladder cancer: Diagnosis and treatment. Am. Fam. Phys. 96, 507–514 (2017).

2. Patel, V. G., Oh, W. K. & Galsky, M. D. Treatment of muscle-invasive and advanced bladder cancer in 2020. CA: Cancer J. Clin. 70, 404–423 (2020).

3. Han, J., Gu, X., Li, Y. & Wu, Q. Mechanisms of BCG in the treatment of bladder cancer-current understanding and the prospect. Biomed.Pharmacother. Biomed. Pharmacother. 129, 110393 (2020).

4. Sánchez Vázquez, A. et al. BCG therapy in NMIBC: How much and for how long?. Archivos Espanoles de Urologia 71, 349–357 (2018).

5. Shore, N. D. et al. Non-muscle-invasive bladder cancer: An overview of potential new treatment options. Urol. Oncol. 39, 642–663 (2021).

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3